Please Wait
Applying Filters...
Digital Content 
NEWS #PharmaBuzz
06 Mar 2024
// ACCESSWIRE
https://www.accesswire.com/839567/salix-pharmaceuticals-announces-a-phase-2-investigator-initiated-study-of-relistor-methylnaltrexone-bromide-mntx-in-patients-with-resectable-head-and-neck-squamous-cell-carcinoma
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216836
https://www.noramco.com/2022/11/01/noramco-announces-submission-and-reactivation-of-the-drug-master-file-for-active-pharmaceutical-ingredient-methylnaltrexone-bromide/
24 Oct 2022
// ACCESSWIRE
https://www.accesswire.com/721607/Salix-Will-Present-XIFAXANR-Rifaximin-TRULANCER-Plecanatide-and-RELISTORR-Methylnaltrexone-Bromide-Data-at-The-American-College-of-GastroenterologyR-2022-Annual-Scientific-Meeting
24 Mar 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/new-data-on-cost-impact-of-treating-opioid-induced-constipation-oic-with-fda-approved-medications-including-salixs-relistor-subcutaneous-injection-methylnaltrexone-bromide-in-the-emergency-department-is-published-in-advanc-301509600.html
28 Feb 2022
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125390
LOOKING FOR A SUPPLIER?
Market Place
Share